RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...

Moderna will continue to lead clinical development and manufacturing for mRNA-3927Moderna to receive up to $160 million ...

CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

In the latest trading session, Moderna (MRNA) closed at $43.00, marking a +2.8% move from the previous day. The stock's change was more than the S&P 500's daily loss of 2.06%. On the other hand, the ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Up to $54.3 million CEPI investment aims to help advance Moderna’s H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic ...

January 26, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 ...